Philadelphia chromosome Ph–like acute lymphoblastic leukemia accounts for more than 20% of all adult patients with ALL and is associated with a poor outcome, according to findings published in the Journal of Clinical Oncology.
January 2017
Robert Dreicer, MD, discusses ongoing developments in mCRPC, including the latest approaches with radium-223.
The growth of the oncology drug pipeline has fueled the emergence of new oral therapies. While these therapies make treatment more convenient, when compared with traditional infused chemotherapy regimens, they also present new challenges, particularly in the area of adherence.
Some key highlights from SITC’s 31st Annual Meeting
Centers for Medicare and Medicaid Services and Rep Nancy Pelosi have confirmed the demise of the Medicare Part B Drug Payment Model experiment to cut margins.
Heather Wakelee, MD, discusses T790M mutation detection among different platforms in an analysis from the TIGER-X trial
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
